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Abstract
BACKGROUND: Worldwide, there is a significant concern regarding the association of breast cancer risk and oral 
contraceptives use. Differences in demographical and pathological breast cancer characteristics in Iraqi patients 
have been reported compared to other western countries; however, studies addressing the risk of breast cancer 
among oral contraceptive users in Iraq and subsequent correlation with hormonal receptor status are lacking.
AIM: The aim of the study was to evaluate association of breast cancer risk and oral contraceptives use in patients 
visiting tertiary oncology center and to correlate hormone receptor status with history of oral contraception use in 
breast cancer patients.
PATIENTS AND METHODS: Two hundred women with breast cancer were compared regarding patterns of oral 
contraceptives use with 300 age-matched healthy female controls by personal interview and questionnaire. Patient’s 
records were reviewed for hormone receptor status.
RESULTS: A significantly higher proportion (49%) of women with breast cancer reported a positive history of 
combined oral contraceptives use as compared with (35.7%) healthy controls. Ever oral contraceptives users had a 
significantly increased risk of breast cancer (odds ratio [OR] = 1.73; 95%, confidence interval = 1.2–2.5, p = 0.003), 
with the highest risk was seen in early use before the age of 20 (OR = 6.62, p = 0.02); whereas increased duration 
of use did not significantly increase the risk of breast cancer. There was no significant association between estrogen 
and progesterone receptors expression profile in breast cancer patients and combined oral contraceptive use.
CONCLUSION: In Iraqi women, the risk of breast cancer increases with oral contraceptives intake particularly when 
starts early before the age of 20 years. The hormonal receptor status of breast cancer patients is not significantly 
affected by combined oral contraceptives use.
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Introduction
Breast cancer is the most common cancer 
worldwide. In Iraq, breast cancer tops cancers for the 
past 30 years, accounting for 19% of all and 33.5% of 
female newly diagnosed cancer cases with incidence 
rate of about 25.8 per 100,000 female population in 
2010. It is the leading cause (22.3%) of female cancer 
related deaths and the second cause (11.3%) of all 
cancer-related deaths [1].
The association between breast cancer and 
exogenous hormonal intake has been a research 
focus for decades. The use of exogenous estrogen in 
the forms of postmenopausal hormone replacement 
therapy (estrogens alone or combined with progestins), 
premenopausal oral contraceptive pills, contraceptive 
injections, or implants has been repeatedly reported as 
possible risk factors of breast cancer, and they were 
shown to have a relative risk (RR) of <2 [2], [3]. In 1996, 
ever oral contraception (OC) users showed a small but 
significant increase risk of breast cancer (RR = 1.07; 
confidence interval [CI], 1.02–1.13) that was unrelated 
to the duration, dose or type of the preparation used and 
a slightly more risk among current users (RR = 1.24; 
CI, 1.15–1.33), which continues 10 years after stopping 
OC (RR = 1.01; CI, 0.96–1.05) [4].
Depending on more than 10 cohort studies 
and 60 case–control studies published up to 2005, 
International Agency of Research on Cancer (IARC) 
concluded in a monograph published in 2007 that the 
best evidence suggested an increase in risk for breast 
cancer among current and recent OC users with more 
increase are seen among females younger than 35 
years of age who started taking OC when they were 
teenagers and that “OC are carcinogenic to humans” [5]. 
More recently, breast cancer incidence was shown to be 
significantly increased in ever users (odds ratio [OR], 
1.08; CI, 1.00–1.17) with a higher risk among recent 
OC use up to 5 years (OR, 1.21; CI, 1.04–1.41) [6].
Furthermore, association between OC use and 
hormone receptors status which is considered important 
prognostic and predictive markers of breast cancer has 
been proposed since 1987 [7]. Studies results, however, 
varied between strong association with ER, PR negative 
cancers [8], [9] to little or no association [10], [11]. More 
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importantly, none of these studies has been done in 
Middle East region, the population of which may differ 
in their contraceptive prevalence and breast cancer 
biological behavior, hence, may not typically reflect the 
condition in Iraq. Therefore, the current study aims to find 
the association between breast cancer risk and OC use 
among Iraqi females and examine the association OC 
use and ER and PR expression in breast cancer patients.
Materials and Methods
This is a hospital-based case–control study 
carried out in the Oncology Teaching Hospital in Baghdad 
Medical City during the period from January 1, 2018, to 
June 1, 2018. The study was approved by Oncology 
Teaching Hospital Ethical Committee and conformed 
to the principles of the Declaration of Helsinki of 1975. 
Informed written consent from study participants was 
secured. The interview was performed in a private setting.
Study groups
A total sample size of 500 was calculated to be 
sufficient to detect a statistically significant difference 
of <0.05 between cases/controls and the relative 
frequency of using OC implying an alpha error of 0.05 
and a study power (1-beta) of 0.95.
The study groups included 200 female patients 
with an established diagnosis of breast cancer (positive 
histopathology and receiving systemic therapy) with no 
positive family history of breast cancer and 300 age-
matched control selected from the first-degree relatives 
of the cases with no previous personal history of non-
invasive breast tumors or benign proliferative breast 
diseases and no previous history of radiation therapy to 
match the genetic and environmental confounders. More 
than one control subjects were invited from each case 
when possible or available to overcome unavailability 
of relative controls for some cases. Participants with 
history of injectable or hormonal loaded intrauterine 
contraceptive device were excluded from the study.
A custom made close ended questionnaire 
form was filled by the participants who were personally 
interviewed gathering data about: Age, marital status, 
number of children, menstrual status, use of OC, 
type, duration of use, and time since first and last use. 
Hospital records were reviewed to obtain data about 
tumor site, histopathological type, stage, and hormonal 
receptors status.
Statistical analysis
Statistical analyses were performed using 
Statistical Package for the Social Sciences (IBM SPSS) 
software version 21 in association with Microsoft Excel 
2013. All continuous data were presented as mean 
and standard deviation. OR and 95% CIs was used 
to measure the strength of association between two 
categorical variables. t-test or Chi-square was used 
to compare between groups when appropriate. Binary 
logistic regression analysis performed to assess the 
relationship between different variables if one or both of 
them follow normal distribution. p < 0.05 was considered 
statistically significant.
Results
Patient demographics
The mean age of breast cancer patient and 
aged-matched healthy control participants was 48.5 
(27–85) and 46 (20–79) years, respectively, which 
showed no statistical difference; almost half of them 
were postmenopausal as shown in Table 1.
Table 1: Study groups demographics and characteristics
Variable Healthy controls Breast cancer patients 
n % n % p-value
Age group (years) 0.15 [NS]
Young (<45) 125 41.7 60 30
Average (45–64) 153 51 126 63
Older (≥65+) 22 7.3 14 7
Postmenopausal compared to menopausal 0.68 [NS]
Reproductive age (premenopausal) 181 60.3 117 58.5
Postmenopausal 119 39.7 83 41.5
Parous compared to nulliparous 0.001
Nulliparous 20 6.7 31 15.5
Parous 280 93.3 169 84.5
Tumor type
Invasive ductal carcinoma - 191 95
Invasive lobular carcinoma - 9 5
Tumor stage
I-II - 74 37
III-IV - 126 63
NS: Non-significant.
The parity status was significantly different 
between the cases and controls (p = 0.001) with 15% 
of the cases were nulliparous women compared to only 
6.7% of the controls (Table 1).
Breast cancer risk and OC
As shown in Table 2, a significantly higher 
proportion (49%) of breast cancer patients gave a 
positive history of OC use compared to healthy controls 
Table 2: Breast cancer risk in OC users according to the age 
of first use
Variable Healthy control Breast cancer patients 95% CI p-value
n % n % OR
Age of first use of OC
Non-users 193 64.3 102 51.0
<20 2 0.7 7 3.5 6.62 (1.35–32.48) 0.02
20–24 17 5.7 12 6.0 1.34 (0.61–2.9) 0.465 [NS]
25–29 19 6.3 18 9.0 1.79 (0.9–3.57) 0.096 [NS]
30–39 52 17.3 46 23.0 1.67 (1.05–2.66) 0.029
≥40 17 5.7 15 7.5 1.67 (0.8–3.48) 0.171 [NS]
Age of first use of OC ≥20 years
Non-user 193 64.3 102 51
<20 2 0.7 7 3.5 6.62 (1.35–32.48) 0.02
≥20 105 35 91 45.5 1.64 (1.13–2.37) 0.009
NS: Non-significant, OC: Oral contraception, OR: Odds ratio, CI: Confidence interval.
B - Clinical Sciences Oncology
1246 https://www.id-press.eu/mjms/index
(35.7%). The type of OC used was combined pills, none 
of the patients or control have had used progesterone 
only pills. The risk of having breast cancer was 
significantly increased by 73% in subjects with a positive 
history of OC use compared to those who never used 
OC. When age at first use of OC was considered, OC 
use at the youngest age (<20 years) associated with 
the highest increase in the risk of having breast cancer 
(6.62 times, p = 0.02, Table 3) compared to non-users. 
The increased risk of having breast cancer for the 
remaining age groups in terms of first OC use ranged 
between 34% and 79% (Table 2). In addition, being 
older than 20 years at first OC use increased the risk of 
having breast cancer by 64% (p = 0.009) compared to 
non-users (Table 2).
Table 3: Breast cancer risk in OC users according to the 
duration of OC use and total OC exposure time
Variable Healthy controls Cases (Breast Ca) 95% CI OR p-value
n % n % OR
Duration of OC use (years)
Never user 193 64.3 102 51
<1 11 3.7 24 12 4.13 (1.94–8.77) <0.001
1–4 years 49 16.3 35 17.5 1.35 (0.82–2.22) 0.234 [NS]
≥5 years 47 15.7 39 19.5 1.57 (0.96–2.56) 0.07 [NS]
Total 300 100 200 100
Total exposure time (OC use + quit time)
None users 193 64.3 102 51.0
<5 20 6.7 17 8.5 1.61 (0.81–3.21) 0.177 [NS]
5–14 48 16.0 28 14.0 1.10 (0.65–1.86) 0.712 [NS]
15–24 23 7.7 23 11.5 1.89 (1.01–3.54) 0.046
≥25 16 5.3 30 15.0 3.55 (1.85–6.82) <0.001
Total 300 100.0 200 100.0
NS: Non-significant, OC: Oral contraception, OR: Odds ratio, CI: Confidence interval.
The short duration of OC use of <1 year was 
associated with an exceptionally higher risk of having 
breast cancer (OR = 4.13) compared to non-users. This 
may be attributed to recall bias. The short duration of use 
(1–4 years) marginally and non-significantly increase 
the risk by 35%, while, 5 years or longer duration of 
OC use showed further increase numerically but was 
statically not significant.
In addition, the total OC exposure time which 
was calculated by adding the duration of using OC and 
the discontinuation time together was assessed against 
the risk of having breast cancer. The longer exposure 
time showed the highest risk to have breast cancer; 
exposure time of 15–24 years was associated with 89% 
increased risk (p = 0.046) compared to non-users while, 
25 years of exposure or more was associate with OR 
of 3.55 (p < 0.001), Table 3. There was no correlation 
between OC use and cancer type or stage.
Hormonal receptors status of breast 
cancer patients and OC use
ER and/or PR positive cases were 150 (75%) 
and 50 (25%) were receptor negative. The association 
between the risk of having positive hormone receptors 
among breast cancer cases and age of first OC use, 
ever OC use, duration of OC use, and total exposure 
time are shown in Table 4. There was no obvious or 
statistically significant association.
Discussion
The association between exogenous steroid 
hormones and breast cancer development was the 
focus of research in the developed countries for the 
past 3 decades, yet the association of OC intake 
and breast cancer in some developing countries in 
particular Iraq has not been well addressed. Several 
studies have pointed out differences in demographical 
and pathological breast cancer characteristics in Iraqi 
patients compared to other western countries [12], [13]. 
Moreover the age of starting OC intake differs from other 
countries due to cultural and social factors prompting 
studying this potential risk factor in Iraqi population.
Table 4: The risk of having positive hormonal receptor by selected explanatory variables among breast cancer cases
Variable Hormone positive Breast Ca OR 95% CI OR p-value
Both ER/PR negative Positive ER and/or PR
n % n %
Age of first use of OC (20+ years)
Non-user 26 52.0 76 50.7
<20 1 2.0 6 4.0 2.05 (0.24–17.87) 0.515 [NS]
20+ 23 46.0 68 45.3 1.01 (0.53–1.94) 0.973 [NS]
Total 50 100.0 150 100.0
Parity
Parous 44 88.0 125 83.3
Nullipara 6 12.0 25 16.7 1.47 (0.56–3.81) 0.432 [NS]
Total 50 100.0 150 100.0
History of ever using OC
Negative 26 52.0 76 50.7
Positive 24 48.0 74 49.3 1.05 (0.56–2) 0.87 [NS]
Total 50 100.0 150 100.0
Duration of OC use (years)-categories four
Never used 26 52.0 76 50.7
<1 6 12.0 18 12.0 1.03 (0.37–2.86) 0.96 [NS]
1–5 years 10 20.0 25 16.7 0.86 (0.36–2.02) 0.721 [NS]
5+ years 8 16.0 31 20.7 1.33 (0.54–3.25) 0.537 [NS]
Total 50 100.0 150 100.0
Total exposure time (OC use + quit time)-categories
None users 26 52.0 76 50.7
<5 6 12.0 11 7.3 0.63 (0.21–1.87) 0.401 [NS]
5-14 5 10.0 23 15.3 1.57 (0.54–4.56) 0.404 [NS]
15–24 7 14.0 16 10.7 0.78 (0.29–2.11) 0.628 [NS]
25+ 6 12.0 24 16.0 1.37 (0.5–3.72) 0.538 [NS]
Total 50 100.0 150 100.0
NS: Non-significant, OC: Oral contraception, OR: Odds ratio, CI: Confidence interval.
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Reviewing literature showed variability in 
calculating the RR of OC use. This was in part, due 
to selecting bias resulting in difficulties in controlling 
cofounders. In this study, we selected the control group 
from the first-degree relatives of patients excluding 
women with past personal of breast cancer, to overcome 
the difficulty of determining the genetic predisposition 
of breast cancer and to reduce the ethnic, social and 
environmental variations between cases and controls 
to the minimum. We also excluded women with history 
of the previous radiation therapy, breast proliferative 
diseases and non-invasive tumors, and we age-
matched both patient and control groups, as all these 
factors known to increase risk of breast cancer to a 
greater extent than OC use [3].
Nulliparity was rated to increase risk of the 
breast cancer with (OR 1.67–1.9) [3]. In Iraqi society, 
OC is predominantly used by married fertile women 
with very little exceptions of some unmarried or infertile 
married women who use OC for stopping bleeding or 
menstrual cycles during limited periods like the fasting 
month (Ramadan) or pilgrimage when women should 
stop worship during the days of cycle, if not stopped 
by medications. This reduces the confounding chance 
of nulliparity as all the nulliparous participants, in this 
study, did not use OC during their lives.
The association between specific OC 
formulations and breast cancer risk remains uncertain. 
Few studies have looked into this, the largest compared 
38 OC formulations and failed to detect a specific OC 
formulation that increase breast cancer risk in a greater 
extent than other formulations [14]. While other study 
done in a younger age group has detected an increased 
risk in current users of triphasic regimens only [15], 
which is not marketed in Iraq according to the data of 
IARC monograph [5], [16]. Combined OC are the most 
commonly used pills by Iraqi women; however, most of 
the participants in the current study were uncertain of 
the OC formulation they had used and some used more 
than one formulation. This fact made the analysis of risk 
association of specific formulation difficult in addition to 
recall bias.
In the present study, ever users have increased 
risk of breast cancer by 73%, this was consistent 
with the extensive evidence of OC association with 
breast cancer stated in IARC monograph, 2007 [16], 
and the more recent systemic review of Gierisch 
et al. [6]. Several case–control studies conducted 
in the neighboring countries, which share relatively 
similar demographic and cultural factors, have shown 
wide variation in results [17], [18]. Consistent with 
a Turkish and an Iranian studies [17], [19], we has 
shown a significant increase risk of breast cancer 
among OC users. Interestingly, the effect of early use 
of OC before age of 20 years further increased the 
risk of breast cancer among Iraqi females irrespective 
of duration of use and time since the last use. This 
is important in the view of the trend toward early 
marriage in Iraqi society and the WHO documented 
estimation of using contraception by 21% of young 
Iraqi females aged 15–19 years [20]. This finding may 
explain the stronger effect of larger total exposure 
time (time since first use) more than 15 years on 
breast cancer among Iraqi females. Consistent with 
IARC pooled study which concluded an increase in 
RR in the subgroup of women <50 years of age at 
diagnosis who had begun using OC when they were 
teenagers [21]. Conversely, Collaborative Group study 
in 1996 had found an increased risk of breast cancer 
in current users continued to 10 years after stopping 
OC (RR = 1.07; CI, 1.02–1.13) but disappear then 
after [4]. All the previously mentioned studies failed to 
detect a time-dependent association of breast cancer 
with duration of OC use, except a cohort study of Van 
Hoften et al. [22] which showed an increased risk but 
only for more than 10 years-use in women older than 
55 years (RR = 2.1; CI, 1.1–4.0) [22]. In the present 
study, trend of positive association between duration 
of OC use and breast cancer risk was noted; however, 
that was statically not significant. The short use for 
<1 year has shown significant increase of cancer the 
risk, but this may be attributed to the recall bias of old 
short interval life events by the control group.
The relationship between hormone receptors 
status and known risk factors of breast cancers, 
including OC use, has been studied previously but in 
a lesser extent comparing to other breast cancer risk 
factors and summarized in Supplementary Table 1.
In our cohort, and consistent with many 
other studies [23], [24], [25], [26], [27], no significant 
association was found between the hormone receptor 
status and the ever OC users, age at first OC use, 
duration of use, age at diagnosis, or parity.
Conversely, some studies reported a significant 
increase in risk of ER/PR –ve breast cancers among 
OC users [28], [29], two of which recruited African 
American women only [8], [29], and other studies 
included only young aged women [28]. A recent large 
study from UK showed that this association is seen 
only among OC users for more than 5 years [30]. A 
single Indian study depicted a significant association of 
hormone positive (ER/PR +ve) breast cancers and pre 
and postmenopausal OC users which was confounded 
by the low prevalence of OC use in India [9].
Conclusion
Oral contraceptives use increases the risk of 
breast cancer among Iraqi females, especially with 
the early use before age of 20 years and those with 
longer exposure time and showed no association with 
hormone receptor status.
B - Clinical Sciences Oncology
1248 https://www.id-press.eu/mjms/index
References
1. Ministry of Health. Iraq Cancer Board, Iraqi Cancer Registry, 
Iraqi Cancer Registry, Republic of Iraq. New Delhi: Ministry of 
Health; 2016.
2. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, 
Homesley HD, et al. Relationship between surgical-
pathological risk factors and outcome in clinical stage I and 
II carcinoma of the endometrium: A gynecologic oncology 
group study. Gynecol Oncol. 1991;40(1):55-65. https://doi.
org/10.1016/0090-8258(91)90086-k
 PMid:1989916
3. Singletary SE. Rating the risk factors for breast cancer. 
Ann Surg. 2003;237(4):474-82. https://doi.org/10.1097/01.
sla.0000059969.64262.87
 PMid:12677142
4. Collaborative Group on Hormonal Factors in Breast 
Cancer. Breast cancer and hormonal contraceptives: 
Collaborative reanalysis of individual data on 53 297 women 
with breast cancer and 100 239 women without breast 
cancer from 54 epidemiological studies. Lancet (London, 
England). 1996;347(9017):1713-27. https://doi.org/10.1016/
s0140-6736(96)90806-5
 PMid:8656904
5. IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans. Combined Estrogen-progestogen Contraceptives and 
Combined Estrogen-Progestogen Menopausal Therapy. Lyon, 
France: IARC Monographs on the Evaluation of Carcinogenic 
Risks to Humans; 2007. p. 1-528. https://doi.org/10.1016/
s0003-2670(97)89591-8
6. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, 
Moorman PG, Lowery WJ, et al. Oral contraceptive use and 
risk of breast, cervical, colorectal, and endometrial cancers: 
A systematic review. Cancer Epidemiol Biomarkers Prev. 
2013;22(11):1931-43. https://doi.org/10.1158/1055-9965.
epi-13-0298
 PMid:24014598
7. Stanford JL, Szklo M, Boring CC, Brinton LA, Diamond EA, 
Greenberg RS, et al. A case-control study of breast cancer 
stratified by estrogen receptor status. Am J Epidemiol. 
1987;125(2):184-94. https://doi.org/10.1093/oxfordjournals.aje.
a114519
 PMid:3812427
8. Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, 
Palmer JR. Oral contraceptive use and estrogen/progesterone 
receptor-negative breast cancer among African American 
women. Cancer Epidemiol Biomarkers Prev. 2010;19(8):2073-9. 
https://doi.org/10.1158/1055-9965.epi-10-0428
 PMid:20647407
9. Tewari M, Pradhan S, Singh U, Shukla HS. Estrogen and 
progesterone receptor status in breast cancer: Effect of 
oral contraceptive pills and hormone replacement therapy. 
Breast (Edinburgh, Scotland). 2007;16(5):540-5. https://doi.
org/10.1016/j.breast.2007.05.005
 PMid:17587581
10. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal 
factors and the risk of breast cancer according to estrogen-and 
progesterone-receptor subgroup. Cancer Epidemiol Biomarkers 
Prev. 2003;12(10):1053-60. https://doi.org/10.1093/aje/kwm216
 PMid:14578142
11. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. 
A case-control study of oral contraceptive use and incident 
breast cancer. Am J Epidemiol. 2009;169(4):473-9. https://doi.
org/10.1093/aje/kwn360
 PMid:19074777
12. Alwan N, Kerr D, Al-Okati D, Pezella F, Nidhal F. Comparative 
study on the clinicopathological profiles of breast cancer among 
Iraqi and British patients. Open Public Health J. 2018;11:177-91. 
https://doi.org/10.2174/1874944501811010177
13. Majid RA, Hassan HA, Muhealdeen DN, Mohammed HA, 
Hughson MD. Breast cancer in Iraq is associated with a 
unimodally distributed predominance of luminal Type B 
over luminal Type A surrogates from young to old age. BMC 
Womens Health. 2017;17(1):27. https://doi.org/10.1186/
s12905-017-0376-0
 PMid:28388952
14. Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, 
Folger SG, et al. Oral contraceptive formulation and risk of 
breast cancer. Contraception. 2012;85(4):342-50. https://doi.
org/10.1016/j.contraception.2011.08.007
 PMid:22067757
15. Beaber EF, Buist DS, Barlow WE, Malone KE, Reed SD, 
Li CI. Recent oral contraceptive use by formulation and breast 
cancer risk among women 20 to 49 years of age. Cancer Res. 
2014;74(15):4078-89. https://doi.org/10.1158/0008-5472.
can-13-3400
 PMid:25085875
16. IARC Working Group on the Evaluation of Carcinogenic Risks 
to Humans. Hormonal Contraception and Post-menopausal 
Hormonal Therapy. Lyon: IARC Monographs; 1998. p. 1-528.
17. Kuru B, Ozaslan C, Ozdemir P, Dinç S, Camlibel M, Alagöl H. 
Risk factors for breast cancer in Turkish women with early 
pregnancies and long-lasting lactation--a case-control study. 
Acta Oncol (Stockholm, Sweden). 2002;41(6):556-61. https://
doi.org/10.1080/02841860214964
 PMid:12546529
18. Karim SM, Baeshen W, Neamatullah SN, Bin B. Oral contraceptives, 
abortion and breast cancer risk: A case control study in Saudi 
Arabia. Asian Pac J Cancer Prev. 2015;16(9):3957-60. https://
doi.org/10.7314/apjcp.2015.16.9.3957
 PMid:25987068
19. Ghiasvand R, Maram ES, Tahmasebi S, Tabatabaee SH. Risk 
factors for breast cancer among young women in southern 
Iran. Int J Cancer. 2011;129(6):1443-9. https://doi.org/10.1002/
ijc.25748
 PMid:21064105
20. World Health Organization. Iraq-statistics Summary 
(2002-Present). Geneva: World Health Organization; 2002. 
Available from: https://www.apps.who.int/gho/data/node.
country.country-IRQ. [Last accessed on 2020 Jan 17].
21. Huzell L, Persson M, Simonsson M, Markkula A, Ingvar C, 
Rose C, et al. History of oral contraceptive use in breast 
cancer patients: Impact on prognosis and endocrine treatment 
response. Breast Cancer Res Treat. 2015;149(2):505-15. 
https://doi.org/10.1007/s10549-014-3252-8
 PMid:25556354
22. Van Hoften C, Burger H, Peeters PH, Grobbee DE, Van Noord PA, 
Leufkens HG. Long-term oral contraceptive use increases breast 
cancer risk in women over 55 years of age: The DOM cohort. 
Int J Cancer. 2000;87(4):591-4. https://doi.org/10.1002/1097-
0215(20000815)87:4<591::aid-ijc20>3.0.co;2-c
 PMid:10918202
23. Anderson KN, Schwab RB, Martinez ME. Reproductive risk 
factors and breast cancer subtypes: A review of the literature. 
Breast Cancer Res Treat. 2014;144(1):1-10. https://doi.
org/10.1007/s10549-014-2852-7
 PMid:24477977
24. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, 
et al. Association between common risk factors and molecular 
 Alsammarraie et al. Breast Cancer and Oral Contraception
Open Access Maced J Med Sci. 2020 Dec 10; 8(B):1244-1250. 1249
subtypes in breast cancer patients. Breast (Edinburgh, 
Scotland). 2013;22(3):344-50. https://doi.org/10.1016/j.
breast.2012.08.005
 PMid:22981738
25. Elwood JM, Godolphin W. Oestrogen receptors in breast 
tumours: Associations with age, menopausal status and 
epidemiological and clinical features in 735 patients. Br J Cancer. 
1980;42(5):635-44. https://doi.org/10.1038/bjc.1980.296
 PMid:7459204
26. Lesser ML, Rosen PP, Senie RT, Duthie K, Menendez-Botet C, 
Schwartz MK. Estrogen and progesterone receptors in breast 
carcinoma: Correlations with epidemiology and pathology. 
Cancer. 1981;48(2):299-309. https://doi.org/10.1002/1097-
0142(19810715)48:2<299::aid-cncr2820480215>3.0.co;2-2
 PMid:7237401
27. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, 
Madigan MP, Sherman ME. Etiology of hormone receptor-
defined breast cancer: A systematic review of the literature. 
Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558-68. 
https://doi.org/10.1016/s1047-2797(03)00136-4
 PMid:15466970
28. Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, 
Daling JR, et al. Oral contraceptives and breast cancer risk 
overall and by molecular subtype among young women. Cancer 
Epidemiol Biomarkers Prev. 2014;23(5):755-64. https://doi.
org/10.1158/1055-9965.epi-13-0944
 PMid:24633144
29. Bethea TN, Rosenberg L, Hong CC, Troester MA, Lunetta KL, 
Bandera EV, et al. A case-control analysis of oral contraceptive 
use and breast cancer subtypes in the African American breast 
cancer epidemiology and risk consortium. Breast Cancer Res. 
2015;17(1):22. https://doi.org/10.1186/s13058-015-0535-x
 PMid:25849024
30. Work ME, John EM, Andrulis IL, Knight JA, Liao Y, Mulligan AM, 
et al. Reproductive risk factors and oestrogen/progesterone 
receptor-negative breast cancer in the breast cancer family 
registry. Br J Cancer. 2014;110(5):1367-77. https://doi.
org/10.1038/bjc.2013.807
 PMid:24548865 
B - Clinical Sciences Oncology
1250 https://www.id-press.eu/mjms/index
Supplementary Table 1: Summary of studies which addressed 
the risk of hormone status in OC users
Authors Country Year n OR p-value
Elwood et al. UK 1980 735 0.83 NS
Lesser et al. USA 1981 784 NA NS
McTiernan et al. USA 1986 240 1.2+
0.8−
NS
NS
Stanford et al. USA 1987 458 0.8+
1.2−
NS
NS
Cooper et al. USA 1989 380 0.88+
1.33−
NS
NS
Huang et al. USA 2000 783 1.5+
1.2−
NS
NS
Britton et al.* USA 2002 1212 1.2+
1.5−
NS
S
McCredie et al.* Australia 2003 618 1.1+
0.9−
NS
NS
Cotterchio et al. Canada 2003 3276 0.9+
1.3−
NS
NS
Althuis et al.* USA 2003 1375 1.6+
3.1−
NS
S
Tewari et al. India 2007 300 2.5 + pre
2.4 + post
S
S
Lumachi et al. Italia 2008 NA R=0.22 S
Kwan et al. USA 2009 2280 Luminal B 0.73
TN 0.97
S
NS
Rosenberg et al.** USA 2010 789 1.11+
1.65–
0.9±
NS
S
NS
Ma et al. USA 2010 1197 NA NS any 
subtype
Phipps et al. USA 2011 2610+
307−
NA NS any 
subtype
Islam et al. Japan 2011 706 0.82 luminal B
069 TN
NS any 
subtype
Turkoz et al. USA 2013 1884 NA NS any 
subtype
Ritte et al. Europe 2013 3567+
998−
0.9+
1.09−
NS
NS
Work et al. UK 2014 4011 0.83+> 5 years
1.35 - >5 years
S
S
Beaber et al.* USA 2014 985 Age 20–39 years
3.5 - >5 years current
3.7 TN >5 years current
S
S
Bethea et al.** USA 2015 1848+
1043−
494 
TN
1.15+
1.24−
1.14TN
S
S
NS
*The study included only young aged patients; **Studies included African Americans; HR+: Hormonal 
receptors ER or PR expressed breast cancers; HR: Breast cancer lacking both ER and PR; Users: OC 
users; NA: This data is not accessible; NS: Non-significant; S: Significant; Pre: Premenopausal patients; 
Post.: Postmenopausal patients; TN: Triple Negative breast cancers.
Supplementary Table
